Davis Polk advised Bausch Health Companies Inc. in connection with the separation of its eye health business into a new publicly traded company, Bausch + Lomb […]
Bausch + Lomb’s $630 Million Initial Public Offering
Amount’s Acquisition of Linear Financial Technologies
Sidley represented Linear Financial Technologies on the deal. Small business loan (SMB) and account origination platform, Linear Financial Technologies, announced its sale to Amount, a banking technology […]
LumiraDx Limited’s Merger Agreement with CA Healthcare Acquisition
Goodwin Procter, Fried Frank and Appleby advised LumiraDx Limited on the deal, while Sidley Austin LLP acted for CA Healthcare Acquisition Corp. LumiraDx Limited announced its […]
Tempest Therapeutics’ Merger With Millendo Therapeutics
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted […]
Tempest Therapeutics’ Merger With Millendo Therapeutics
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted […]